Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of Hepatitis C
Introduction and Objectives: Previous studies have evaluated the risk of drug-drug interactions (DDI) in HCV patients receiving pangenotypic direct-acting antivirals (pDAA), but all are based on pairwise interaction. The aim of the study was to describe the prevalence of the risk of potential multip...
Main Authors: | J Mendez-Navarro, J Turnes, A García-Herola, R Morillo, M Méndez, M Rueda, C Hernández, A Sicras-Mainar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268122001661 |
Similar Items
-
P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C
by: Juan Turnes, et al.
Published: (2023-03-01) -
Pangenotypic Direct Acting Antivirals Treatment for Chronic Hepatitis C Infection
by: Juferdy Kurniawan
Published: (2020-07-01) -
Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
by: Dorota Zarębska-Michaluk, et al.
Published: (2022-01-01) -
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023-01-01) -
Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
by: Dorota Zarębska-Michaluk, et al.
Published: (2021-07-01)